444 related articles for article (PubMed ID: 34513661)
1. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon
Tan J; Hu C; Deng P; Wan R; Cao L; Li M; Yang H; Gu Q; An J; Jiang J
Front Oncol; 2021; 11():646577. PubMed ID: 34513661
[TBL] [Abstract][Full Text] [Related]
2. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
3. Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study.
Zhou J; Qin H; Miao J; Liu R; Wang W
Medicine (Baltimore); 2023 Jun; 102(26):e34110. PubMed ID: 37390279
[TBL] [Abstract][Full Text] [Related]
4. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
Chen C; Zhang C; Lin H; Liu Q; Wu L; Zhou C; Zhang J
Ther Adv Chronic Dis; 2022; 13():20406223221125706. PubMed ID: 36274751
[TBL] [Abstract][Full Text] [Related]
5. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
6. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
7. Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients.
Deng Q; Xie B; Wu L; Ji X; Li C; Feng L; Fang Q; Bao Y; Li J; Jin S; Ding C; Li Y; Zhou S
Heliyon; 2018 Dec; 4(12):e01031. PubMed ID: 30603682
[TBL] [Abstract][Full Text] [Related]
8. Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation.
Dong W; Wang C; Wang C; Zhao K; Ma Z; Hu S
Front Oncol; 2022; 12():999606. PubMed ID: 36425553
[TBL] [Abstract][Full Text] [Related]
9. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
[TBL] [Abstract][Full Text] [Related]
10. Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
Lei L; Wang WX; Zhu YC; Li JL; Fang Y; Wang H; Zhuang W; Zhang YB; Wang LP; Fang MY; Xu CW; Wang XJ; Lv TF; Song Y
Cancer Med; 2020 Jan; 9(1):12-18. PubMed ID: 31692291
[TBL] [Abstract][Full Text] [Related]
11. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.
Qu J; Wang YN; Xu P; Xiang DX; Yang R; Wei W; Qu Q
Oncotarget; 2017 May; 8(20):33961-33971. PubMed ID: 28430623
[TBL] [Abstract][Full Text] [Related]
13. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L
PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047
[TBL] [Abstract][Full Text] [Related]
14. Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India.
Singh V; Nambirajan A; Malik PS; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Mohan A; Jain D
Lung Cancer; 2020 Nov; 149():53-60. PubMed ID: 32971387
[TBL] [Abstract][Full Text] [Related]
15. Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study.
Qin Y; Long Y; Tang Y; Tian Y; Li J; Duan P; Luo J; Yu M; Li Y; Zhou X; Wang K; Gong Y; Peng F; Zhu J; Liu Y; Zhou L; Lu Y; Huang M
Cancer Sci; 2023 Jun; 114(6):2552-2559. PubMed ID: 36851884
[TBL] [Abstract][Full Text] [Related]
16. Uncommon
Shi J; Yang H; Jiang T; Li X; Zhao C; Zhang L; Zhao S; Liu X; Jia Y; Wang Y; Xi L; Zhang S; Su C; Ren S; Zhou C
Chin J Cancer Res; 2017 Dec; 29(6):543-552. PubMed ID: 29353977
[TBL] [Abstract][Full Text] [Related]
17. Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon
Jung HA; Park S; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
Biology (Basel); 2020 Oct; 9(10):. PubMed ID: 33036377
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.
Kanazu M; Mori M; Kimura M; Nishino K; Shiroyama T; Nagatomo I; Ihara S; Komuta K; Suzuki H; Hirashima T; Kumagai T; Imamura F
Thorac Cancer; 2021 Jan; 12(1):90-96. PubMed ID: 33124128
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
20. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]